Evidence map›Paper›PMID 35111297›Full record

ArticleTherapeutic advances in psychopharmacology2022

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.

Ebenezer Oloyede, Ivana Clark, Shubhra Mace, Eromona Whiskey, David Taylor

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Antidepressant Augmentation of Antipsychotic Treatment in Schizophrenia: A Narrative Review.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Ebenezer OloyedePharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0003-1352-4017
Ivana ClarkPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.
Shubhra MacePharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0001-9548-7533
Eromona WhiskeyPharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK.ORCID https://orcid.org/0000-0002-6146-0073
David TaylorPharmacy Department, South London and Maudsley NHS Foundation Trust, London SE5 8AZ, UK.ORCID https://orcid.org/0000-0002-2557-1710
King's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Only about 50% of patients with treatment-resistant schizophrenia respond to clozapine, and many more patients continue to experience ongoing and prominent negative symptoms. These negative symptoms, for which there are limited pharmacological options, may represent the greatest barrier to functional recovery. Cariprazine is a novel antipsychotic drug that is a partial agonist at dopamine D

Indexed as

augmentationcariprazineclozapine

Identifiers

PMID35111297
PMCPMC8801710
OpenAlexW4210638551

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.